Inhaled mRNA therapy takes on solid tumors in first human trial
NCT ID NCT07657611
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests an inhaled mRNA immunotherapy for adults with advanced lung cancer or solid tumors that have spread to the lungs. The treatment is given as a dry powder through an inhaler. The main goal is to check safety and find the best dose, with 60 participants expected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Inhaled mRNA dry powder formulation
- What this could lead to
- If it works, this could point toward a new way to treat advanced solid tumors using inhaled mRNA immunotherapy, potentially offering a non-invasive option.
- What could go wrong
- This is an early-phase trial with only 60 participants, focused on safety and dosing. It is too soon to know if it will be effective, and there may be unknown side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple screening program could transform cancer aftercare
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can engineered immune cells target a common ovarian cancer protein?